Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma

• Status: Completed
• Trial end date: 2014-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the safety and tolerability of AZD 1208 up to a maximum tolerated dose (MTD) and define the dose(s) for further clinical evaluation when given daily to patients with advanced solid malignancies including malignant lymphoma

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca

Criteria

Inclusion Criteria:

• Patients who have signed this Written Informed Consent Form after a full explanation about the participation in this study

• Patients aged 18 years or older Patients diagnosed with a solid malignant tumour or malignant lymphoma that is refractory to standard therapies or for which no standard therapies exist

• Patients with good physical conditions (you can walk and can look after yourself) within the last 2 weeks.

• Patients who have at least one lesion that can be accurately assessed

Exclusion Criteria:

• Patients who have recently received or are receiving prohibited medications or treatments

• Patients who have any unresolved side effects of previous treatments

• Patients who have spinal cord compression or brain metastases

• Patients who have severe systemic diseases (e.g., uncontrolled hypertension, hepatitis B, hepatitis C and human immunodeficiency virus [HIV] infection)

• Patients with significant abnormal ECG findings